Does [ KRAS mutation influence oxaliplatin or irinotecan efficacy , in association with bevacizumab , in first line treatment of metastatic colorectal cancer ]?
In this retrospective study, KRAS mutational status does not influence the efficacy of first line cytotoxic chemotherapy in association with bevacizumab.
The present study shows that hydrogen sulfide induces systemic inflammation and multiple organ damage characteristic of sepsis via transient receptor potential vanilloid type 1-mediated neurogenic inflammation.